Nehal Parikh, MD
|Education:||BA, Rutgers University, 1993
MD Ross University School of Medicine, 1998
|Residency:||Pediatrics, State University of New York, 1998-2001|
|Fellowship:||Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center,
Assistant Professor of Pediatrics, University of Connecticut School of Medicine
Dr. Parikh has developed specialized expertise in the management of childhood solid tumor, with a particular research interest on advancing the care of children with Neuroblastoma. Dr. Parikh’s expertise and interest in Neuroblastoma has led to his ongoing involvement at the Children’s Oncology Group to develop treatment strategies for children with high risk Neuroblastoma. Recently, he was invited to join a nationally recognized consortium which helps develop novel therapies for children with advanced disease. His partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) will provide novel therapeutic options for children with relapse or refractory Neuroblastoma and Medulloblastoma and other childhood solid tumor malignancies in our region. Dr. Parikh is a principal investigator for these phase 1 and 2 clinical trials, and is also in the process of helping develop another novel approach to cancer therapeutics, which will help develop personalized therapies to target the individual patient’s specific cancer genetic makeup. Dr. Parikh is the lead physician charged with developing an international outreach program to help advance the care of children with Neuroblastoma in low-income countries. In partnership with St. Jude’s Children’s Research Hospital and Children’s Oncology Group, he has contributed to an international platform for consultative discussion and education with physicians caring for children with challenging cases in pediatric cancers.
- Sholler GL, Ferguson W, Bergendahl B, Currier E, Lenox SR, Bond J, Slavik M, Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna, G, Eugster E, Cherba D, Miller J and Webb C. A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy, 2012. (In press)
- Scarpato KR, Makari JH, Agaronov M, Balarezo F, Parikh N, Finck CM, Ferrer FA. Primary renal synovial sarcoma in a 13-year old boy. J Pediatr Surg. 2011 Sep;46(9):1849-51.
- Takeda K, Aguila H, Parikh N, Li X, Lamothe K, Duan Li-Juan, Takeda H, Lee F, Fong Guo-Hua. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood, 2008 March: 111:3229-3235.
- Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky H, Parikh N, Habrukowich C, Hla T. Vascular Endothelium As a contributor of plasma sphingosine 1-phosphate. Circulation Research, 2008 March 28;102:1-8.
- Venkataraman K, Thaganda S, Michaud J, Oo ML, Ai Y, Lee YM, Wu M, Parikh N, Khan F, Proia RL, Hla T. Extracellular export of Sphingosine Kinase-1a contributes to a vascular S1P gradient. Biochemical Journal, 2006 Aug 1; 397(3): 461-71.
- Parikh NS*, Currier MA, Mahller YY, Adams LC, Di Pasquale B, Collins MH, Cripe TP. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer. 2005 May;44(5):469-78.
- Parikh NS*, Hoyer JD, Cripe TP. A young girl with hemolytic anemia and elevated hemoglobin F. Pediatr Blood Cancer. 2005 Mar;44(3):264-6.